Table 2.
Age group (years) | Pre-vaccination |
10 years post-vaccination |
||||||
---|---|---|---|---|---|---|---|---|
Carriage prevalence | VTa | Strong NVTb | Weak NVT | Carriage prevalence | VT | Strong NVT | Weak NVT | |
<1 | 80.8 (67.8–90.1) | 32.6 (25.1–40.5) | 37.5 (30.6–45.8) | 9.9 (7.1–13.2) | 75.7 (61.4–87.2) | 8.3 (1.6–18.2) | 50.9 (40.9–62.6) | 15.2 (10.5–22.2) |
1–5 | 72.5 (65.2–78.5) | 29.5 (23.9–35.2) | 29.7 (24.6–35.2) | 13.1 (9.6–17.0) | 67.2 (58.9–74.6) | 8.0 (1.5–16.9) | 39.2 (32.2–48.5) | 19.3 (14.1–25.5) |
6–14 | 54.0 (43.1–64.8) | 17.0 (13.9–21.2) | 26.8 (18.9–35.0) | 9.9 (7.4–13.5) | 49.7 (38.6–61.0) | 4.4 (0.9–9.6) | 32.0 (23.6–41.2) | 12.8 (9.5–17.1) |
15–20 | 27.9 (17.0–41.7) | 9.1 (5.7–13.9) | 13.4 (7.6–20.7) | 5.3 (3.1–8.6) | 25.3 (15.6–38.0) | 2.5 (0.5–6.0) | 15.8 (9.5–24.3) | 6.8 (4.1–10.8) |
21–49 | 25.5 (17.0–35.5) | 8.6 (5.8–12.1) | 12.0 (7.6–17.5) | 4.8 (3.0–7.2) | 23.2 (15.2–33.0) | 2.5 (0.5–5.6) | 14.2 (9.2–20.9) | 6.2 (3.9–9.3) |
50+ | 21.0 (14.0–30.0) | 7.1 (4.7–10.1) | 9.8 (6.2–14.6) | 4.0 (2.6–6.0) | 19.1 (12.7–27.3) | 2.0 (0.4–4.5) | 11.7 (7.6–17.2) | 5.2 (3.3–7.9) |
Overall | 44.4 (40.2–48.9) | 15.9 (13.3–18.7) | 20.4 (16.8–24.2) | 8.0 (6.1–10.2) | 40.8 (36.0–46.0) | 4.3 (0.8–9.1) | 25.4 (21.2–30.0) | 10.9 (8.4–13.8) |
Vaccine serotypes.
Non-vaccine serotypes.